HYDRALYTE_1170x120

generic drug industry

Where would we be with no generics?

Where would we be with no generics?

The numbers are in for medication spending in the U.S. for the year 2015. And the story headline could read: Thank You, Generic Medication Industry. Another headline for the same story could read: Alarming U.S. Medication Cost Increase of 12% for 2015. Both headlines would be defensibly accurate. The details are in the continuing bifurcation

Teva to buy Allergan Generics for $40.5 billion

Teva to buy Allergan Generics for $40.5 billion

JERUSALEM — Teva Pharmaceutical Industries Ltd. plans to buy Allergan’s generic drug business for about $40.5 billion and, with the deal, has withdrawn its proposal to acquire Mylan N.V. for approximately $40 billion. Teva said Monday that Dublin, Ireland-based Allergan will receive $33.75 billion in cash and $6.75 billion in shares of Teva. The agreement

Generics drugs loom larger than ever in health care

Generics drugs loom larger than ever in health care

NEW YORK — As the nation becomes more focused on affordable health care, generic drug companies are carving out a larger share of the U.S. market for prescription drugs. Perhaps the most significant sign of this continuing shift to generic drug utilization shows up in the market share data for actual prescriptions dispensed, brands compared

Neas to leave GPhA in the autumn

WASHINGTON — Ralph Neas, president and chief executive officer of the Generic Pharmaceutical Association, has announced he will step down from his position in the fall. Neas has led GPhA since September 2011. During his remaining tenure, he will continue to serve as CEO until a successor is named and will work to ensure a